7. A community desires to start a dermatology residency that will be completely funded by a pharmaceutical company.
#	Response Date	Comment
1.	Tue, 3/13/07 11:57 PM	Depends on whether the drug company will be involved in the residency or merely provided an endowment.
2.	Wed, 3/14/07 12:10 AM	Depends on whether it is an unrestricted grant or has strings attached (the latter is likely)
3.	Wed, 3/14/07 12:23 AM	What strings are attached, if no strings then no COI
4.	Wed, 3/14/07 12:34 AM	If the pharmaceutical company has no influence on the curriculum, there would be no COI.
5.	Wed, 3/14/07 12:54 AM	see above
6.	Wed, 3/14/07 1:55 AM	It really depends. It depends if it is a part of an independent grant, and if there is some system in place for oversite.
7.	Wed, 3/14/07 3:17 AM	Depends on the degree of independence the residency program has from the company
8.	Wed, 3/14/07 12:43 PM	no COI if certain conditions are met, i.e. the clinic has right to practice, research, publish, teach without cohersion or reestrictions of any kind by the company and full disclosures are made
9.	Wed, 3/14/07 1:48 PM	Control exerted by company on any aspect of operations.
10.	Wed, 3/14/07 1:50 PM	Could be serious, depends on the terms of the funding.
11.	Wed, 3/14/07 2:04 PM	Needs disclosure but it is unlikely that it would not be serious COI
12.	Wed, 3/14/07 3:31 PM	a conflict if the company places requirements or restrictions on the resident and/or the program
13.	Wed, 3/14/07 7:51 PM	Is there such a thing as "unrestriced residency funding"?
14.	Wed, 3/14/07 10:00 PM	will residents be required to prescribe medications based on merit and data?
15.	Thu, 3/15/07 12:57 AM	No COI as long as the association is made clear and patients are not required to buy products from that company.
16.	Thu, 3/15/07 4:56 PM	It depends on the nature of the agreement to establish the residency. YES, if the company has some authority over the establishment of the residency program.
17.	Mon, 3/19/07 12:03 AM	NO COI if the sponsoring company does not control the curriculum
18.	Mon, 3/19/07 4:08 PM	Depends on the agreements for funding and expectations.
19.	Mon, 3/19/07 5:23 PM	Not enough facts here.
20.	Tue, 3/20/07 4:53 AM	provided the pharmaceutical company is not the one producing medications that will be prescribed to patients and no contract to use agents produced by the company exclusively. and the administration of the dermatology program is completely different from the pharmaceutical company. That is the company must not be in control of the residency program
21.	Thu, 3/29/07 1:34 PM	don't know how common this is
22.	Mon, 4/23/07 1:06 PM	As far as I know, this is very unusual. It would need to be clearly stated in the contract that any medication would be prescribed and no financial reimbursement would go to the pharmaceutical company. If medication was more limited, then it would be a very serious COI.
23.	Mon, 4/23/07 10:28 PM	It depends on the way the funding is set up and the kind of the meds that the phamaceutical company sells.
24.	Tue, 4/24/07 12:48 AM	If the pharmaceutical company develops dermatology products then this is a verys serious COI
25.	Wed, 4/25/07 5:27 PM	It depends on the kinds of product the pharmaceutical company makes. If it is a Dermatology company, it is a Moderate COI. If it makes no dermatolgy products, it is a small COI
26.	Thu, 4/26/07 11:38 AM	The contingency clause in the funding contract will determine the seriousness or lack thereof.
27.	Thu, 4/26/07 9:16 PM	It would be difficult to understand how this could be done via an unrestricted educational grant (preferably thru the institutions foundation) but this would be the minimum
28.	Tue, 5/1/07 12:20 AM	It depends on if the pharmaceutical comapny in any way influences the perscription drugs offered at the clinic.
29.	Tue, 5/8/07 10:05 PM	As long as the education of the resident os in no way affected by the company there should not be a problem
30.	Wed, 5/9/07 12:52 PM	An unrestricted grant with proper contractual language to avoid industry pressure and regulation of program content and drug use may not be an issue. This arrangement does seem highly unusual though.
31.	Mon, 5/14/07 12:59 AM	If the endowment for the department is not contingent on special access to this companies pharma rep or increased product sales probably OK but smells a little.
32.	Tue, 5/15/07 4:28 PM	IF the company requires the exclusive use of their products/services - serious problem. If the funding is "no strings attached," less of a COI.